Another study has shown that Eph receptor A4 (EphA4) is overexpressed in PDAC and promotes cancer cell growth [10], suggesting that EphA4 is a likely prognostic factor or a molecular target for therapy of PDAC. Here, EPHA4 is linked to cancer.